Amplia Therapeutics (ASX:ATX) said initiation activities for its pancreatic cancer trial in the US have started, focusing on the combination of the company's focal adhesion kinase inhibitor narmafotinib with chemotherapy Folfirinox for advanced pancreatic cancer patients, according to a Wednesday filing with the Australian bourse.
The company partnered with a contract research organization to manage clinical trial activities in the US, the filing said.
The trial will be run under the investigational new drug application for narmafotinib which was cleared by the US Food and Drug Administration, per the filing.
Shares rose nearly 2% in recent trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.